Ascletis Gains FDA Clearance for Once-Monthly Obesity Drug Trial

The upcoming trial will enroll 84 participants, targeting individuals with obesity or those who are overweight with related health conditions. Researchers will conduct the study in two distinct stages: an initial single ascending dose assessment followed by a head-to-head comparison against the FDA-authorized tirzepatide. By utilizing its proprietary Self-Assembling Lipid Depot technology, Ascletis aims to achieve a controlled, slow release of the medication over a full month.

Preclinical data suggest a significant performance edge for the candidate. In non-human primate studies, ASC35 exhibited a half-life approximately six times longer than that of tirzepatide. Furthermore, tests on diet-induced obese mice indicated that the drug achieved 71% greater relative body weight reduction compared to the market-leading treatment. Company leadership anticipates that these pharmacokinetic advantages, paired with a less frequent dosing regimen, will address critical gaps in current obesity management.